Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease

Phase 3

Not yet recruiting

Conditions: Interstitial Lung Disease
Systemic Sclerosis

Interventions: Drug: Tocilizumab
Drug: Nintedanib
Drug: Standard therapy

First Posted Date: 2024-03-06

Last Posted Date: 2024-11-20

Lead Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Target Recruit Count: 86

Registration Number: NCT06297096

Locations: 🇵🇱
Centrum Wsparcia Badań Klinicznych, Warsaw, Mazowieckie, Poland

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB800
Drug: Actemra

First Posted Date: 2024-02-16

Last Posted Date: 2024-12-12

Lead Sponsor: Biogen

Target Recruit Count: 300

Registration Number: NCT06262477

Locations: 🇬🇧
Fortrea Clinical Research Unit Inc., Leeds, West Yorkshire, United Kingdom

Plan Development for Giving Teclistamab in the Outpatient Setting

Phase 4

Not yet recruiting

Conditions: Multiple Myeloma
Relapsed Cancer
Refractory Cancer

Interventions: Drug: Teclistamab
Drug: Tocilizumab

First Posted Date: 2024-02-09

Last Posted Date: 2024-08-26

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 15

Registration Number: NCT06251076

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Phase 2

Active, not recruiting

Conditions: Interleukin-6
Ischemic Stroke
Endovascular Treatment

Interventions: Drug: Tocilizumab
Drug: NaCl 0.9% 100ml

First Posted Date: 2024-02-02

Last Posted Date: 2024-07-18

Lead Sponsor: Suzhou Municipal Hospital of Anhui Province

Target Recruit Count: 108

Registration Number: NCT06238024

Locations: 🇨🇳
Suzhou Municipal Hospital of Anhui Province, Suzhou, Anhui, China

Efficacy and Safety of Tocilizumab for TAO

Phase 2

Withdrawn

Conditions: Tocilizumab
Thyroid Associated Ophthalmopathy

Interventions: Drug: Tocilizumab

First Posted Date: 2023-10-18

Last Posted Date: 2023-11-28

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT06087731

Locations: 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Phase 3

Recruiting

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Obinutuzumab
Drug: Glofitamab
Drug: Bendamustine
Drug: Tocilizumab
Drug: Lenalidomide

First Posted Date: 2023-10-16

Last Posted Date: 2024-12-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 182

Registration Number: NCT06084936

Locations: 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺
Epworth Hospital, Richmond, Victoria, Australia

and more 59 locations

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Richter's Transformation

Interventions: Drug: Glofitamab
Drug: Obinutuzumab
Drug: Tocilizumab
Drug: Polatuzumab Vedotin
Drug: Atezolizumab

First Posted Date: 2023-09-21

Last Posted Date: 2024-05-28

Lead Sponsor: Christine Ryan

Target Recruit Count: 66

Registration Number: NCT06043674

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Tocilizumab in Lung Transplantation

Phase 2

Recruiting

Conditions: Lung Transplant

Interventions: Drug: Placebo for Tocilizumab
Drug: Tocilizumab

First Posted Date: 2023-09-13

Last Posted Date: 2024-08-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 350

Registration Number: NCT06033196

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix, Arizona, United States
🇺🇸
Cedars Sinai Medical Center (Site #: 71146), Los Angeles, California, United States
🇺🇸
David Geffen School of Medicine at UCLA (Site #: 71123), Los Angeles, California, United States

and more 13 locations